CVRx to Present at the Jefferies Global Healthcare Conference in London

Core Insights - CVRx, Inc. is a commercial-stage medical device company focused on innovative neuromodulation solutions for cardiovascular diseases [3] - The management team will present at the Jefferies Global Healthcare Conference in London on November 18, 2025 [1] - The presentation will be available via live audio webcast on the company's investor relations page [2] Company Overview - CVRx specializes in developing, manufacturing, and commercializing neuromodulation solutions, with Barostim™ being its flagship product [3] - Barostim is the first FDA-approved medical technology that uses neuromodulation to alleviate symptoms in heart failure patients [3] - The device delivers electrical pulses to baroreceptors in the carotid artery, aiming to restore balance to the autonomic nervous system [3] - Barostim has received FDA Breakthrough Device designation and is approved for use in heart failure patients in the U.S. [3] - The device is also compliant with EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic Area [3]